시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 샘플 요청 목록
세계의 비스포스포네이트 의약품 시장 보고서(2025년)
Bisphosphonate Drug Global Market Report 2025
상품코드 : 1764262
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 175 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,310,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,121,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 11,932,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

비스포스포네이트 의약품 시장 규모는 향후 수년간 강력한 성장이 전망됩니다. 2029년의 연간 평균 성장률(CAGR)은 5.9%로 성장할 전망이며, 66억 6,000만 달러로 성장이 예측됩니다. 예측 기간 중 예상되는 성장의 원동력은 비스포스포네이트 의약품의 제네릭 의약품 입수 가능성 증가, 세계 인구의 급속한 고령화, 골감소증 발견률 상승, 암에 의한 골합병증 급증, 규제당국에 의한 적극적인 가이드라인, 예방 헬스케어 중시 고조 등입니다. 주요 새로운 동향으로는 경구 제제에 대한 기호 증가, 약물 전달 시스템의 혁신, 디지털 툴의 이용에 의한 환자의 도입, 유전자 프로파일에 의한 개별화 치료 접근법, 예측적 건강 모니터링을 위한 AI 기술의 채택 등을 들 수 있습니다.

골다공증의 이환율의 상승은 향후 수년간 비스포스포네이트 의약품 시장의 성장을 가속할 것으로 예측됩니다. 골다공증은 골밀도 저하로 쉽게 골절되는 뼈의 약화를 특징으로 하는 질환입니다. 골다공증의 유병률 증가는 세계 인구의 고령화에 기인하는 바가 크고, 골밀도는 나이가 들면서 자연스럽게 저하되기 때문에 생활습관 요인이나 불충분한 예방 의료도 더해지고 있습니다. 비스포스포네이트 의약품은 뼈의 분해를 지연시킴으로써 뼈를 강화하고 골절 위험을 낮춤으로써 골다공증을 치료합니다. 예를 들어서 2024년 8월에 Healthy Bones Australia가 발표한 보고에 따르면 2023년에는 골다공증과 골감소증 관련 골절이 약 19만 3,482건 발생했습니다. 이 수는 2033년에는 34% 증가한 23만 7,632명이 될 것으로 예측되고 있습니다. 그 결과 골다공증 환자 수의 증가가 비스포스포네이트 의약품 시장의 성장에 박차를 가하고 있습니다.

비스포스포네이트 의약품 시장의 주요 기업은 제품 접근을 확대하고 시장 경쟁을 강화하고 진화하는 안전성 및 유효성의 기준을 준수하기 위해 규제 당국의 승인을 중시하고 있습니다. 규제 당국의 승인은 정부 보건 기관에 의해 부여되어 안전성과 유효성을 확인한 후 기업이 의약품을 판매하는 것을 허가하는 것입니다. 예를 들면, 2025년 3월, 한국의 바이오 의약품 회사인 셀트리온은, 바이오시밀러인 스토보쿠로(데노스맙-bmwo)와 오셈베르트(데노스맙-bmwo)의 미국 FDA 승인을 취득했습니다. 스토보클로는 폐경 후 여성과 남성의 골다공증, 글루코코르티코이드 유발성 골다공증, 특정 암 치료로 인한 골량 감소 등 다양한 골다공증 관련 질환의 치료로 승인되고 있습니다. 한편, 오셈베르트는 다발성 골수종 또는 골전이 환자에서 골합병증 예방, 골거세포종 치료, 악성종양에 따른 고칼슘혈증 관리 등 암과 관련된 골격 문제에 적응이 가능합니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향 및 전략

제4장 시장 : 금리, 인플레이션, 지정학, 무역전쟁 및 관세, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석 및 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별 및 국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도 및 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹 및 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문 및 전략

제36장 부록

AJY
영문 목차

영문목차

Bisphosphonates are a class of medications that help prevent bone density loss. They are widely prescribed to manage or prevent osteoporosis and other bone-related conditions by inhibiting the processes that lead to bone degradation. The primary goal of bisphosphonates is to enhance bone strength and lower the risk of fractures, particularly in patients diagnosed with osteoporosis.

The principal types of bisphosphonate medications include alendronate, risedronate, and zoledronic acid. Alendronate is commonly used to prevent and treat osteoporosis by reducing bone resorption and promoting bone mass gain. These drugs are available in both oral and intravenous formulations and are distributed through hospital pharmacies, retail outlets, online pharmacies, and other channels. They are used for various indications, such as postmenopausal osteoporosis, male osteoporosis, Paget's disease, cancer therapy-induced bone loss, glucocorticoid-induced osteoporosis, and more. The end users of these drugs include hospitals, clinics, home care environments, and other healthcare settings.

The bisphosphonate drug market research report is one of a series of new reports from The Business Research Company that provides bisphosphonate drug market statistics, including bisphosphonate drug industry global market size, regional shares, competitors with a bisphosphonate drug market share, detailed bisphosphonate drug market segments, market trends and opportunities, and any further data you may need to thrive in the bisphosphonate drug industry. This bisphosphonate drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The bisphosphonate drug market size has grown strongly in recent years. It will grow from $4.98 billion in 2024 to $5.28 billion in 2025 at a compound annual growth rate (CAGR) of 6.2%. This expansion during the historical period was fueled by the rising incidence of osteoporosis, greater public awareness regarding bone health, widespread usage of drugs like alendronate and risedronate, a growing demographic of postmenopausal women, and increased demand for therapies related to bone cancer and metastasis.

The bisphosphonate drug market size is expected to see strong growth in the next few years. It will grow to $6.66 billion in 2029 at a compound annual growth rate (CAGR) of 5.9%. The anticipated growth during the forecast period will be driven by the increased availability of generic bisphosphonates, a rapidly aging global population, higher detection rates of osteopenia, a surge in bone complications from cancer, proactive guidelines from regulatory bodies, and a heightened emphasis on preventive healthcare. Key emerging trends include the growing preference for oral formulations, innovations in drug delivery systems, the use of digital tools to engage patients, personalized treatment approaches based on genetic profiles, and the adoption of AI technologies for predictive health monitoring.

The rising incidence of osteoporosis is expected to drive the growth of the bisphosphonates drug market in the coming years. Osteoporosis is a condition marked by weakened bones that are more susceptible to fractures due to decreased bone density. The growing prevalence of osteoporosis is largely attributed to the aging global population, as bone density naturally declines with age, along with lifestyle factors and inadequate preventive care. Bisphosphonate drugs treat osteoporosis by slowing bone degradation, thereby strengthening bones and lowering the risk of fractures. For example, in August 2024, Healthy Bones Australia reported that in 2023, there were approximately 193,482 fractures associated with osteoporosis and osteopenia. This number is projected to increase by 34% to 237,632 fractures by 2033. As a result, the rising number of osteoporosis cases is fueling the growth of the bisphosphonates drug market.

Leading companies in the bisphosphonate drug market are emphasizing regulatory approvals to expand product access, enhance market competitiveness, and comply with evolving safety and efficacy standards. Regulatory approvals, granted by government health agencies, authorize companies to market and sell their drugs after confirming they are safe and effective. For instance, in March 2025, Celltrion, Inc., a biopharmaceutical firm based in South Korea, received U.S. FDA approval for its biosimilars STOBOCLO (denosumab-bmwo) and OSENVELT (denosumab-bmwo). STOBOCLO is approved for treating various osteoporosis-related conditions, including osteoporosis in postmenopausal women and men, glucocorticoid-induced osteoporosis, and bone loss from specific cancer treatments. OSENVELT, on the other hand, is indicated for cancer-related skeletal issues such as preventing bone complications in patients with multiple myeloma or bone metastases, treating giant cell tumor of bone, and managing malignancy-associated hypercalcemia.

In May 2023, Abiogen Pharma S.p.A., a pharmaceutical company based in Italy, acquired EffRx Pharmaceuticals SA for an undisclosed sum. This acquisition was aimed at strategically strengthening and diversifying Abiogen's rare disease portfolio by incorporating EffRx's innovative treatments for musculoskeletal and rare disorders. It also helps Abiogen expand its international reach and capabilities in developing and commercializing specialized therapies globally. EffRx Pharmaceuticals SA, located in Switzerland, is a specialty pharmaceutical firm that produces and markets bisphosphonate drugs for osteoporosis treatment.

Major players in the bisphosphonate drug market are Pfizer Inc., Roche Holding AG, Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma Ltd, Dr. Reddy's Laboratories Ltd., Cipla Ltd., Hikma Pharmaceuticals, Zydus Lifesciences Ltd., Alkem Laboratories, Natco Pharma Ltd., Strides Pharma, Radius Health Inc., EffRx Pharmaceuticals, Warner Chilcott, and Abiogen Pharma S.p.A.

North America was the largest region in the bisphosphonate drug market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in bisphosphonate drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the bisphosphonate drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The bisphosphonate drug market consists of sales of products including oral tablets, bisphosphonate capsules, bisphosphonate injections, oral solutions, and intravenous (IV) infusions. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Bisphosphonate Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on bisphosphonate drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for bisphosphonate drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The bisphosphonate drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Bisphosphonate Drug Market Characteristics

3. Bisphosphonate Drug Market Trends And Strategies

4. Bisphosphonate Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Bisphosphonate Drug Growth Analysis And Strategic Analysis Framework

6. Bisphosphonate Drug Market Segmentation

7. Bisphosphonate Drug Market Regional And Country Analysis

8. Asia-Pacific Bisphosphonate Drug Market

9. China Bisphosphonate Drug Market

10. India Bisphosphonate Drug Market

11. Japan Bisphosphonate Drug Market

12. Australia Bisphosphonate Drug Market

13. Indonesia Bisphosphonate Drug Market

14. South Korea Bisphosphonate Drug Market

15. Western Europe Bisphosphonate Drug Market

16. UK Bisphosphonate Drug Market

17. Germany Bisphosphonate Drug Market

18. France Bisphosphonate Drug Market

19. Italy Bisphosphonate Drug Market

20. Spain Bisphosphonate Drug Market

21. Eastern Europe Bisphosphonate Drug Market

22. Russia Bisphosphonate Drug Market

23. North America Bisphosphonate Drug Market

24. USA Bisphosphonate Drug Market

25. Canada Bisphosphonate Drug Market

26. South America Bisphosphonate Drug Market

27. Brazil Bisphosphonate Drug Market

28. Middle East Bisphosphonate Drug Market

29. Africa Bisphosphonate Drug Market

30. Bisphosphonate Drug Market Competitive Landscape And Company Profiles

31. Bisphosphonate Drug Market Other Major And Innovative Companies

32. Global Bisphosphonate Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Bisphosphonate Drug Market

34. Recent Developments In The Bisphosphonate Drug Market

35. Bisphosphonate Drug Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기